Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5technology 3unknown 3
Ambient AI scribes are generating wiretapping and biometric privacy lawsuits because health systems deployed without patient consent protocols for third-party audio processing
Ambient AI scribes are facing an unanticipated legal attack vector through wiretapping and biometric privacy statutes. Lawsuits filed in California and Illinois (2025-2026) allege health systems used ambient scribing without patient informed consent, potentially violating: California's Confidentiali
FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable
FDA explicitly acknowledged concern about 'how HCPs interpret CDS outputs' in the 2026 guidance, formally recognizing automation bias as a real phenomenon. However, the agency's proposed solution reveals a fundamental misunderstanding of the mechanism: FDA requires transparency about data inputs and
Ambient AI scribes create simultaneous malpractice exposure for clinicians, institutional liability for hospitals, and product liability for manufacturers while operating outside FDA medical device regulation
Ambient AI scribes create a novel three-party liability structure that existing malpractice frameworks are not designed to handle. Clinician liability: physicians who sign AI-generated notes containing errors (fabricated diagnoses, wrong medications, hallucinated procedures) bear malpractice exposur
FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events
MAUDE recorded only 943 adverse events across 823 FDA-cleared AI/ML devices from 2010-2023—an average of 0.76 events per device over 13 years. For comparison, FDA reviewed over 1.7 million MDRs for all devices in 2023 alone. This implausibly low rate is not evidence of AI safety but evidence of surv
Clinical AI chatbot misuse is a documented ongoing harm source not a theoretical risk as evidenced by ECRI ranking it the number one health technology hazard for two consecutive years
ECRI, the most credible independent patient safety organization in the US, ranked misuse of AI chatbots as the #1 health technology hazard in both 2025 and 2026. This is not theoretical concern but documented harm tracking. Specific documented failures include: incorrect diagnoses, unnecessary testi
FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality
Of 429 FDA MAUDE reports associated with AI/ML-enabled medical devices, 148 reports (34.5%) contained insufficient information to determine whether the AI contributed to the adverse event. This is not a data quality problem but a structural design gap: MAUDE lacks the fields, taxonomy, and reporting
FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance
FDA's revised CDS guidance introduces enforcement discretion for CDS tools that provide a single output where 'only one recommendation is clinically appropriate' — explicitly including AI and generative AI. Covington notes this 'covers the vast majority of AI-enabled clinical decision support tools
Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
The FDA's January 6, 2026 CDS enforcement discretion expansion and ECRI's January 2026 publication of AI chatbots as the #1 health technology hazard occurred in the same 30-day window. This temporal coincidence represents the clearest evidence that deregulation is occurring during active harm accumu
The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
The clinical AI safety vacuum operates at both ends of the deployment lifecycle. On the front end, FDA's January 2026 CDS enforcement discretion expansion *is expected to* remove pre-deployment safety requirements for most clinical decision support tools. On the back end, this paper documents that M
Medically tailored meals produce -9.67 mmHg systolic BP reductions in food-insecure hypertensive patients — comparable to first-line pharmacotherapy — suggesting dietary intervention at the level of structural food access is a clinical-grade treatment for hypertension
The Kentucky MTM pilot enrolled 75 food-insecure hypertensive adults across urban (UK HealthCare) and rural (Appalachian Regional Healthcare) sites. The medically tailored meals arm (5 meals/week for 12 weeks) produced -9.67 mmHg systolic BP reduction, while the grocery prescription arm ($100/month
food insecurity independently predicts 41 percent higher cvd incidence establishing temporality for sdoh cardiovascular pathway
The CARDIA prospective cohort study followed 3,616 US adults without preexisting CVD from 2000 to 2020 (mean baseline age 40.1 years, 56% female, 47% Black). Food insecurity at baseline was associated with HR 1.41 for incident CVD after adjustment for income, education, and employment. This is the f
food as medicine interventions produce clinically significant improvements during active delivery but benefits fully revert when structural food environment support is removed
A randomized controlled trial presented at AHA 2025 examined DASH-style grocery delivery plus dietitian support versus cash stipends in food-insecure Black adults in Boston. During the 12-week active intervention, the groceries + dietitian arm showed statistically significant BP improvement and LDL
Rural food-insecure populations enrolled in food assistance interventions at 81 percent versus 53 percent in urban settings, suggesting rural populations may be more receptive to food-based health interventions due to more severe baseline food access constraints
The Kentucky pilot's two-site design revealed a striking enrollment disparity: Appalachian Regional Healthcare (rural) enrolled 26 of 32 referred patients (81%), while UK HealthCare (urban Lexington) enrolled 49 of 92 referred patients (53%). This 28-percentage-point gap suggests rural food-insecure
SNAP receipt reduces antihypertensive medication nonadherence by 13.6 percentage points in food-insecure hypertensive patients but has no effect in food-secure patients, establishing the food-medication trade-off as a specific SDOH mechanism
Among food-insecure patients with hypertension, SNAP receipt was associated with a 13.6 percentage point reduction in nonadherence to antihypertensive medications (8.17 pp difference between SNAP recipients vs. non-recipients in the food-insecure group). Critically, SNAP showed NO association with i
SNAP benefit loss causes measurable mortality increases in under-65 populations through food insecurity pathways with peer-reviewed rate estimates of 2.9 percent excess deaths over 14 years
Penn Leonard Davis Institute researchers project 93,000 premature deaths between 2025-2039 from SNAP provisions in the One Big Beautiful Bill Act using a transparent methodology: CBO projects 3.2 million people under 65 will lose SNAP benefits; peer-reviewed research quantifies mortality rates compa
five adverse sdoh independently predict hypertension risk food insecurity unemployment poverty low education inadequate insurance
A systematic review published in *Hypertension* (AHA journal) analyzed 10,608 records and identified 57 studies meeting inclusion criteria. The review establishes that multiple SDOH domains independently predict both hypertension prevalence and poor blood pressure control: (1) education — higher edu
racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms
The systematic review finds that Black adults have significantly higher hypertension prevalence compared to White adults even when controlling for both individual poverty status AND neighborhood poverty status. This persistence of racial disparity after accounting for standard SDOH measures (income,
tempo pilot creates medicare digital health pathway while medicaid coverage contracts
The TEMPO pilot represents the first combined FDA enforcement-discretion + CMS reimbursement pathway for digital health devices, explicitly targeting hypertension in the 'early cardio-kidney-metabolic' category. Up to 10 manufacturers per clinical area can deploy uncleared devices to Medicare patien
generic digital health deployment reproduces existing disparities by disproportionately benefiting higher income users despite nominal technology access equity
This study of racially diverse, lower-income populations found that despite high smart device ownership, utilization of remote patient monitoring (RPM), medical apps, and wearables remained significantly lower than in higher-income populations. Medical app usage was significantly lower among individ
hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure
The JACC Data Report analyzing 1999–2023 US cardiovascular disease mortality trends reveals a critical divergence: while ischemic heart disease mortality declined during the statin era, hypertensive disease mortality nearly doubled from approximately 23 per 100,000 in 2000 to 43 per 100,000 in 2019,
semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator
The SELECT trial prespecified analysis (N=17,604, semaglutide 2.4mg weekly vs placebo) found no evidence that semaglutide's MACE reduction was mediated by time-varying weight loss. The benefit was consistent across ALL baseline BMI and waist circumference categories, with no treatment heterogeneity
only 23 percent of treated us hypertensives achieve blood pressure control demonstrating pharmacological availability is not the binding constraint
The JACC study tracking 1999-2023 NHANES data reveals a striking failure mode in US cardiometabolic disease management. Among patients already receiving treatment for hypertension, only 23.4% (95% CI: 21.5%-25.2%) achieved blood pressure control by 2021-2023 criteria. More dramatically, the proporti
pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling
PCSK9 inhibitors (evolocumab, alirocumab) demonstrated 15% MACE reduction in FOURIER (2017) and ODYSSEY OUTCOMES (2018) trials on top of statin therapy—proven individual efficacy with FDA approval and ACC/AHA guideline endorsement. Yet population penetration remained catastrophically low: only 0.9%
enhanced aca premium tax credit expiration creates second simultaneous coverage loss pathway above medicaid income threshold
The expiration of enhanced ACA premium tax credits (APTCs) at the end of 2025 creates a structurally distinct coverage loss mechanism from OBBBA's Medicaid cuts. Enhanced APTCs, enacted in the American Rescue Plan Act (2021) and extended through the Inflation Reduction Act (2022), provided substanti
medicare fiscal pressure forces ma reform by 2030s through arithmetic not ideology
Medicare Advantage (MA) reform will be forced by fiscal arithmetic, not ideology, by the 2030s.
Page 10 of 13